Insider Transactions in Q4 2025 at Fennec Pharmaceuticals Inc. (FENC)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 31
2025
|
Robert Andrade CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,430
+1.38%
|
-
|
|
Oct 31
2025
|
Rosty Raykov |
BUY
Grant, award, or other acquisition
|
Direct |
5,208
+5.34%
|
-
|
|
Oct 10
2025
|
Chris A Rallis |
SELL
Open market or private sale
|
Direct |
1,775
-3.02%
|
$15,975
$9.24 P/Share
|
|
Oct 10
2025
|
Chris A Rallis |
BUY
Exercise of conversion of derivative security
|
Direct |
4,062
+6.46%
|
$4,062
$1.23 P/Share
|
|
Oct 09
2025
|
Southpoint Capital Advisors LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,609
-0.51%
|
$185,481
$9.35 P/Share
|
|
Oct 08
2025
|
Southpoint Capital Advisors LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
19,605
-0.48%
|
$176,445
$9.47 P/Share
|
|
Oct 08
2025
|
Rosty Raykov |
BUY
Exercise of conversion of derivative security
|
Direct |
4,609
+5.03%
|
$9,218
$2.45 P/Share
|
|
Oct 07
2025
|
Southpoint Capital Advisors LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
26,900
-0.66%
|
$242,100
$9.59 P/Share
|
|
Oct 06
2025
|
Rosty Raykov |
SELL
Open market or private sale
|
Direct |
10,000
-10.81%
|
$90,000
$9.78 P/Share
|